Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirsi Talala

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
European Urology Oncology|December 6, 2024
Long-term Risk of Prostate Cancer Mortality Among Men with Baseline Prostate-specific Antigen Below 3 ng/ml: Evidence from the Finnish Randomized Study of Screening for Prostate CancerIdris O Ola, Kirsi Talala, Teuvo Tammela, et al.
The Journal of Urology|February 21, 2017
Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor UseTeemu J Murtola, Anniina Virkku, Kirsi Talala, et al.
Cancer Medicine|June 6, 2020
Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancerKirsi Talala, Sirpa Heinävaara, Kimmo Taari, et al.
European Urology Focus|July 30, 2017
Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory DrugsTeemu Johannes Murtola, Arla M Vettenranta, Kirsi Talala, et al.
Plos One|November 6, 2019
Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register dataNeill Booth, Pekka Rissanen, Teuvo L J Tammela, et al.
International Journal of Cancer|January 18, 2019
Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancerAntti Lindberg, Kirsi Talala, Paula Kujala, et al.
Cancer Epidemiology|November 28, 2016
What explains the differences between centres in the European screening trial? A simulation studyJaakko Nevalainen, Ulf-Håkan Stenman, Teuvo L Tammela, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 3, 2021
Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based CohortVille J Vihervuori, Kirsi Talala, Kimmo Taari, et al.
Cancer|October 13, 2020
Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)Tomi Pakarainen, Jaakko Nevalainen, Kirsi Talala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2018
The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)Tomi Pakarainen, Jaakko Nevalainen, Kirsi Talala, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
European Urology Oncology|December 6, 2024
Long-term Risk of Prostate Cancer Mortality Among Men with Baseline Prostate-specific Antigen Below 3 ng/ml: Evidence from the Finnish Randomized Study of Screening for Prostate CancerIdris O Ola, Kirsi Talala, Teuvo Tammela, et al.
The Journal of Urology|February 21, 2017
Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor UseTeemu J Murtola, Anniina Virkku, Kirsi Talala, et al.
Cancer Medicine|June 6, 2020
Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancerKirsi Talala, Sirpa Heinävaara, Kimmo Taari, et al.
European Urology Focus|July 30, 2017
Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory DrugsTeemu Johannes Murtola, Arla M Vettenranta, Kirsi Talala, et al.
Plos One|November 6, 2019
Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register dataNeill Booth, Pekka Rissanen, Teuvo L J Tammela, et al.
International Journal of Cancer|January 18, 2019
Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancerAntti Lindberg, Kirsi Talala, Paula Kujala, et al.
Cancer Epidemiology|November 28, 2016
What explains the differences between centres in the European screening trial? A simulation studyJaakko Nevalainen, Ulf-Håkan Stenman, Teuvo L Tammela, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 3, 2021
Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based CohortVille J Vihervuori, Kirsi Talala, Kimmo Taari, et al.
Cancer|October 13, 2020
Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)Tomi Pakarainen, Jaakko Nevalainen, Kirsi Talala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2018
The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)Tomi Pakarainen, Jaakko Nevalainen, Kirsi Talala, et al.
Pageof 7